Ras

Cat. No.

A63753

CAS No.

2670380-74-0

KRAS G12C inhibitor 45

KRAS G12C inhibitor 45 is a selective inhibitor that targets the KRAS G12C mutation, which plays a crucial role in various cancers. This compound demonstrates significant biological activity by inhibiting the downstream signaling pathways associated with KRAS G12C, thereby inducing apoptosis in tumor cells harboring this mutation. It is a valuable tool for cancer research, particularly in studies focusing on personalized medicine and targeted therapies for KRAS G12C-positive tumors.

Cat. No.

A63756

CAS No.

2411786-50-8

KRAS inhibitor-21

KRAS inhibitor-21 is a potent inhibitor targeting the KRAS G12C mutation with an IC50 value of less than 0.01 μM. This compound demonstrates significant biological activity in attenuating KRAS-mediated signaling pathways, making it a valuable tool for investigating mechanisms of oncogenic transformation. It is particularly useful in cancer research aimed at exploring therapeutic strategies for KRAS-driven malignancies.

Cat. No.

A63757

CAS No.

3054800-66-4

KRAS inhibitor-34

KRAS inhibitor-34 is a selective inhibitor targeting the KRAS protein, exhibiting an IC50 of 6.4 nM. This compound is utilized in tumor research to investigate KRAS-mediated signaling pathways and its role in cancer progression. It provides a valuable tool for studying the therapeutic potential of KRAS inhibition in various malignancies.

Cat. No.

A63758

CAS No.

192185-68-5

(Rac)-Tipifarnib

Synonyms: (Rac)-IND 58359; (Rac)-R115777

(Rac)-Tipifarnib is a potent farnesyl protein transferase inhibitor that disrupts the post-translational modification of Ras proteins. By inhibiting farnesylation, it effectively interferes with the activation and function of Ras, leading to significant antitumor effects. This compound is utilized in research focused on cancer therapeutics and the molecular mechanisms underlying Ras-mediated signaling pathways.

Cat. No.

A63759

CAS No.

2066572-01-6

PAT-IN-2

PAT-IN-2 is a selective inhibitor of protein acyl transferases (PAT), primarily targeting Erf2 autopalmitoylation. By competitively inhibiting this process, PAT-IN-2 serves as a valuable tool for investigating the role of PAT in cellular signaling and lipid metabolism. Its application in research may provide insights into the regulation of protein function via acylation and the development of therapeutic strategies targeting related pathways.

Cat. No.

A63760

CAS No.

2966924-24-1

KRASG12C IN-18

KRASG12C IN-18 is a potent covalent inhibitor targeting the KRASG12C mutation. It effectively engages KRASG12C in both GDP- and GMPPNP-bound states, demonstrating significant antiproliferative activity against KRASG12C and its resistance variants, including KRASG12C/R68S, with low nanomolar IC50 values. This compound exhibits substantial in vivo efficacy in models of KRASG12C-driven solid tumors and KRASG12C/R68S xenografts, making it a valuable tool for research in colorectal cancer.

Cat. No.

A63761

CAS No.

2765091-21-0

RAS-IN-4

RAS-IN-4 is a RAS inhibitor that exhibits significant antitumor activity. This compound interferes with RAS signaling pathways, making it an important tool for researchers studying cancer biology and therapeutic resistance. RAS-IN-4 can be utilized in various in vitro and in vivo studies aimed at understanding the role of RAS in tumor progression and exploring targeted cancer therapies.

Cat. No.

A63762

CAS No.

2066571-97-7

PAT-IN-1

PAT-IN-1 is a selective inhibitor of protein acyl transferases (PAT), specifically targeting Erf2 autopalmitoylation. It acts through competitive inhibition, thereby altering lipid modifications that influence protein functionality. This compound is valuable for research applications exploring the role of palmitoylation in cellular signaling and protein interactions.

Cat. No.

A63763

CAS No.

664975-73-9

ZCL279

ZCL279 is a small molecule modulator that selectively inhibits the interaction between Cdc42 and intersectin (ITSN). At lower concentrations (

Cat. No.

A63764

CAS No.

2648552-62-7

KRAS G12D inhibitor 13

KRAS G12D inhibitor 13 is a selective inhibitor targeting the KRAS G12D mutation, a critical driver in various cancers. This compound effectively disrupts KRAS-mediated signaling pathways, demonstrating potent anti-cancer activity. It serves as a valuable tool for studying the role of KRAS G12D in tumor biology and evaluating potential therapeutic strategies for KRAS-related malignancies.

Cat. No.

A63766

CAS No.

2648551-39-5

KRAS G12D inhibitor 9

KRAS G12D inhibitor 9 is a selective inhibitor targeting the KRAS G12D mutant protein, a crucial element in oncogenic signaling pathways. This compound exhibits significant anti-cancer activity, making it a valuable tool for research focused on KRAS G12D-mediated tumors. Its application is vital for elucidating the mechanisms of KRAS-driven malignancies and developing targeted therapies for patients harboring this mutation.

Cat. No.

A63767

CAS No.

2670380-82-0

ZG1077

ZG1077 is a covalent inhibitor targeting the KRAS G12C mutation. It demonstrates potent inhibitory activity against KRAS-driven cancer cell proliferation, making it a valuable tool for studying non-small cell lung cancer (NSCLC) and other KRAS-related malignancies. This compound facilitates research into therapeutic strategies aimed at inhibiting the KRAS signaling pathway.

Cat. No.

A63770

CAS No.

1404-59-7

Oligomycin D

Synonyms: Rutamycin A

Oligomycin D, an antibiotic derived from the strain S. rutgersensis, functions as a potent inhibitor of K-Ras plasma membrane localization. By disrupting K-Ras localization, Oligomycin D plays a critical role in cancer research, offering insights into tumorigenesis and potential therapeutic strategies. Its use in various cancer studies provides valuable data for understanding K-Ras-driven malignancies.

Cat. No.

A63771

CAS No.

3061844-70-7

RAS-IN-5

RAS-IN-5 is a potent RAS inhibitor that effectively disrupts the interaction between RAF1 and active KRAS mutant or wild-type HRAS proteins. This compound demonstrates significant inhibition of cell viability in KRAS, NRAS, and EGFR mutant cell lines. RAS-IN-5 is valuable for research applications focused on colorectal cancer, liver cancer, and non-small cell lung cancer, providing a critical tool for understanding RAS signaling and its role in tumorigenesis.

Cat. No.

A63774

CAS No.

2761218-40-8

KRAS inhibitor-11

KRAS inhibitor-11 is a potent inhibitor targeting the KRAS protein, which plays a critical role in cell signaling pathways associated with cancer proliferation. This compound exhibits significant anti-proliferative effects in KRAS-driven tumors, making it a valuable tool for cancer research. It is suitable for studies focusing on KRAS mutations and their implications in oncogenic signaling and therapeutic resistance.

Cat. No.

A63775

CAS No.

2648584-52-3

KRAS G12C inhibitor 26

KRAS G12C Inhibitor 26 is a selective inhibitor targeting the mutant form of KRAS G12C. This compound exhibits significant antitumor activity by disrupting downstream signaling pathways associated with cell proliferation and survival. It is primarily utilized in cancer research for evaluating therapeutic strategies against KRAS-driven malignancies and understanding the role of KRAS mutations in tumorigenesis.

Cat. No.

A63776

CAS No.

2326523-41-3

KRAS G12C-IN-72

KRAS G12C-IN-72 is a selective inhibitor targeting the KRAS G12C mutant protein. This compound exhibits potent activity against KRAS G12C, making it valuable for cancer research, particularly in therapeutic development. It can also serve as a ligand for synthesizing PROTACs, such as KRAS degrader-1, facilitating innovative approaches in targeted protein degradation studies.

Cat. No.

A63777

CAS No.

3034052-35-9

KRASG12D-IN-4

KRASG12D-IN-4 is a potent inhibitor of the KRAS G12D mutation, exhibiting an IC50 of 3.3 nM. This compound effectively reduces the proliferation of pancreatic cancer ASPC-1 cells, with an IC50 of 12 nM. KRASG12D-IN-4 serves as a valuable tool in cancer research, particularly for studying the therapeutic potential of targeting KRAS mutations in oncology.

Cat. No.

A63778

CAS No.

3102130-17-3

KRAS G12D-IN-34

KRAS G12D-IN-34 is a potent inhibitor specifically targeting the KRAS G12D mutation, exhibiting IC50 values of 1.05 nM and 1.59 μM for KRAS G12D and wild-type KRAS, respectively. This compound is valuable for research focused on non-small cell lung cancer (NSCLC), providing insights into therapeutic strategies for KRAS-driven tumors. Its selective action enables detailed studies of KRAS-related pathways and potential treatment options.

Cat. No.

A63779

CAS No.

3056974-05-8

KRAS inhibitor-32

KRAS inhibitor-32 targets the KRAS protein, a critical component in many oncogenic signaling pathways. This compound exhibits selective inhibition of KRAS, making it a valuable tool for cancer research, particularly in the study of tumor growth and progression in KRAS-driven malignancies. Its application in preclinical studies can aid in understanding the therapeutic potential of KRAS inhibition in various cancer types.

Cat. No.

A63780

CAS No.

2660014-65-1

KRAS G12C inhibitor 41

KRAS G12C inhibitor 41 is a selective inhibitor targeting the KRAS G12C mutant protein, a critical player in oncogenic signaling pathways. This compound demonstrates significant anti-cancer activity, making it a valuable tool for investigating KRAS G12C-mediated malignancies. Its application in research can facilitate the development of targeted therapies aimed at overcoming resistance mechanisms in cancer treatment.

Cat. No.

A63781

CAS No.

2761968-93-6

KRAS G12C inhibitor 53

KRAS G12C inhibitor 53 is a selective inhibitor targeting the G12C mutated form of the KRAS protein. This compound demonstrates potent anti-proliferative activity in KRAS G12C-driven cancer cell lines, making it a valuable tool in oncology research. It is applicable for studies focused on signaling pathways involved in tumorigenesis and the development of targeted therapies for KRAS G12C mutations.

Cat. No.

A63782

CAS No.

2648985-02-6

KRAS G12C inhibitor 33

KRAS G12C Inhibitor 33 selectively targets the KRAS G12C mutant, inhibiting its activity. This compound is essential for investigating the mechanisms of KRAS-driven cancers and contributes to the development of targeted therapies. It is a valuable tool for cancer research, particularly in studies focused on signaling pathways associated with KRAS mutations.

Cat. No.

A63783

CAS No.

1286482-29-8

ZINC57632462

ZINC57632462 (ACA-6) is a non-covalent allosteric inhibitor targeting KRAS. It effectively disrupts nucleotide exchange and impairs RAS-effector interaction, making it a valuable tool for investigating KRAS-related signaling pathways. This compound is particularly relevant for cancer research, enabling studies focused on tumorigenesis and therapeutic interventions.

Cat. No.

A63785

CAS No.

1616622-10-6

(±)-Spiro-oxanthromicin A

(±)-Spiro-oxanthromicin A is a K-Ras inhibitor with an IC50 value of 26.7 μM. This polyketide compound is derived from soil-isolated Streptomyces sp. and has been shown to mislocalize oncogenic mutant K-Ras from the plasma membrane in intact MDCK cells. (±)-Spiro-oxanthromicin A serves as a valuable tool for cancer research, particularly in studies targeting K-Ras-related pathways.